However, without satisfactory results, Bapineuzumab, an antibody against Tau that causes fibrillary tangles, was tested by Pfizer, and they reported clinical results from their trial, which found that Bapineuzumab had no benefit for mental function in people with mild to moderate AD [15]. The gene discussed is MAPT; the disease is Alzheimer disease.